医药生物
Search documents
万亿并购市场奏响“冰与火之歌”
2 1 Shi Ji Jing Ji Bao Dao· 2025-12-25 01:20
(原标题:万亿并购市场奏响"冰与火之歌") 一半海水,一半火焰。 2025年行至尾声,如行业所料,在"并购六条"等政策暖风之下,2025年的A股并购市场迎来了久违繁 荣。 Wind数据显示,今年以来,截至12月23日,A股市场更新的并购重组事件达到6074单(含涉及多家上市 公司的同一重组事件重复统计,下同)。其中,重大重组数量达到279单,比去年全年增长接近两倍,已 披露的交易总金额高达1.87万亿元,较去年全年增长超过十倍。 然而,繁荣之下,暗流汹涌。今年更新的重大交易中,有四分之一以失败收场,其中不乏大市值科技公 司发起的产业并购、同一控制权下的交易等。 "乘兴而来,败兴而归",不仅是大多数并购从业者的内心写照,亦是部分二级市场投资者挥之不去的阴 影。 年中终止的华大九天定增收购芯和半导体、年末终止的海光信息吸收合并中科曙光……从筹划到终止引 发的股价波动,在资本市场引发了不小的争议。年初终止的海尔生物吸收合并上海莱士,虽然因筹划时 间短没有引起股价波动,但复牌后海尔生物股价也出现大跌。 "重大资产重组由于涉及众多环节,本来失败的概率就比较高。而今年市场氛围比较火热,很多企业不 管是从提升质量的角度,还 ...
揭秘年内72单重大重组失利,半导体赛道失败率高
Xin Lang Cai Jing· 2025-12-25 01:00
Core Viewpoint - The A-share merger and acquisition (M&A) market has seen a significant revival in 2025, with a total of 6,074 M&A events reported, including 279 major restructurings, marking a nearly twofold increase from the previous year. The total disclosed transaction amount reached 1.87 trillion yuan, over ten times higher than last year. However, one-quarter of these major transactions ended in failure, highlighting underlying challenges in the market [1][3][12]. Group 1: Market Performance - The number of major restructuring events in the A-share market has increased significantly, with 279 major restructurings reported this year, compared to 72 last year [1][3]. - The total disclosed transaction amount for M&A activities reached 1.87 trillion yuan, reflecting a growth of over ten times compared to the previous year [1][3]. - The approval rate for M&A applications in the Shanghai, Shenzhen, and Beijing stock exchanges reached 100%, with 39 companies' applications reviewed this year, a 160% increase from last year [3][12]. Group 2: Reasons for Failure - A total of 72 major restructurings failed this year, primarily due to market factors such as changes in market conditions, disagreements on valuation, and inconsistent interests among minority shareholders [3][12]. - The semiconductor and biopharmaceutical sectors experienced higher failure rates, with 12 and 8 failed restructurings, respectively, attributed to significant valuation discrepancies and the nature of their business models [4][5][12]. - Notable failed transactions included the merger between Haier Biomedical and Shanghai Laister, which was terminated after only 15 days of planning, indicating a trend of rapid failures in the current market [6][15]. Group 3: Market Dynamics - The current market environment has led to impulsive M&A decisions, with companies eager to initiate transactions without thorough negotiations, resulting in many deals being called off [2][11]. - The introduction of new IPO policies has influenced companies' attitudes towards M&A, with many firms reassessing their strategies in light of the evolving regulatory landscape [5][14]. - The phenomenon of "flash crash" terminations has become more common, with 18 failed restructurings occurring within 100 days of announcement, indicating a lack of adequate negotiation time [6][15]. Group 4: Investor Behavior - Investors are advised to be cautious of "hype-driven" restructurings, focusing on whether the M&A aligns with the company's long-term strategy and whether there is substantial synergy [8][17]. - The speculative nature of some M&A announcements has led to significant stock price fluctuations, with examples of companies experiencing over 400% price increases before ultimately failing to complete their transactions [7][17]. - The market's reaction to M&A announcements has been volatile, with many investors engaging in irrational speculation, particularly in sectors like semiconductors and renewable energy [7][16].
揭秘年内72单重大重组失利,半导体赛道失败率高
21世纪经济报道· 2025-12-25 00:57
一半海水,一半火焰。 2025年行至尾声,如行业所料,在"并购六条"等政策暖风之下,2025年的A股并购市场迎来了 久违繁荣。 Wind数据显示,今年以来,截至12月23日,A股市场更新的并购重组事件达到6074单(含涉 及多家上市公司的同一重组事件重复统计,下同)。其中, 重大重组数量达到279单,比去年 全年增长接近两倍,已披露的交易总金额高达1.87万亿元,较去年全年增长超过十倍 。 然而,繁荣之下,暗流汹涌。今年更新的重大交易中, 有四分之一以失败收场 ,其中不乏大 市值科技公司发起的产业并购、同一控制权下的交易等。 "乘兴而来,败兴而归",不仅是大多数并购从业者的内心写照,亦是部分二级市场投资者挥之 不去的阴影。 年中终止的华大九天定增收购芯和半导体、年末终止的海光信息吸收合并中科曙光……从筹划 到终止引发的股价波动,在资本市场引发了不小的争议。年初终止的海尔生物吸收合并上海莱 士,虽然因筹划时间短没有引起股价波动,但复牌后海尔生物股价也出现大跌。 "重大资产重组由于涉及众多环节,本来失败的概率就比较高。而今年市场氛围比较火热,很 多企业不管是从提升质量的角度,还是从二级市场的角度,都有一种很紧迫地 ...
72单重大重组折戟 万亿并购市场奏响“冰与火之歌”
2 1 Shi Ji Jing Ji Bao Dao· 2025-12-24 11:24
一半海水,一半火焰。 2025年行至尾声,如行业所料,在"并购六条"等政策暖风之下,2025年的A股并购市场迎来了久违繁 荣。 Wind数据显示,今年以来,截至12月23日,A股市场更新的并购重组事件达到6074单(含涉及多家上市 公司的同一重组事件重复统计,下同)。其中,重大重组数量达到279单,比去年全年增长接近两倍, 已披露的交易总金额高达1.87万亿元,较去年全年增长超过十倍。 然而,繁荣之下,暗流汹涌。今年更新的重大交易中,有四分之一以失败收场,其中不乏大市值科技公 司发起的产业并购、同一控制权下的交易等。 "乘兴而来,败兴而归",不仅是大多数并购从业者的内心写照,亦是部分二级市场投资者挥之不去的阴 影。 年中终止的华大九天定增收购芯和半导体、年末终止的海光信息吸收合并中科曙光……从筹划到终止引 发的股价波动,在资本市场引发了不小的争议。年初终止的海尔生物吸收合并上海莱士,虽然因筹划时 间短没有引起股价波动,但复牌后海尔生物股价也出现大跌。 "重大资产重组由于涉及众多环节,本来失败的概率就比较高。而今年市场氛围比较火热,很多企业不 管是从提升质量的角度,还是从二级市场的角度,都有一种很紧迫地想开始并 ...
主力资金丨尾盘大幅加仓股出炉
Zheng Quan Shi Bao Wang· 2025-12-24 11:21
Group 1 - The electronic industry saw a net inflow of 4.916 billion yuan, leading the market [1] - The A-share market indices collectively rose, with the Shanghai Composite Index achieving six consecutive days of gains [1] - Among the 13 industries with net inflows, the power equipment and defense industries also saw significant inflows of 2.217 billion yuan and 1.233 billion yuan, respectively [1] Group 2 - A total of 45 stocks experienced net inflows exceeding 200 million yuan, with 15 stocks seeing inflows over 400 million yuan [2] - Demingli topped the list with a net inflow of 955 million yuan, driven by increasing data storage demand influenced by AI [2] - Tianji Co. reached a trading limit with a net inflow of 885 million yuan, focusing on the industrialization of lithium sulfide material preparation [2] Group 3 - At the market close, there was a net inflow of 129 million yuan, with the communication sector leading with over 500 million yuan in inflows [3] - Individual stocks such as Zhongji Xuchuang and Qingshan Paper experienced net inflows exceeding 200 million yuan [3] Group 4 - Beijing Junzheng and Wolong Electric Drive saw net outflows exceeding 100 million yuan at the market close [4] - Companies like Midea Group and Sihua Intelligent Control had net outflows exceeding 70 million yuan [5]
11.41亿元资金今日流出医药生物股
Zheng Quan Shi Bao Wang· 2025-12-24 09:51
Market Overview - The Shanghai Composite Index rose by 0.53% on December 24, with 26 out of the 28 sectors experiencing gains, led by the defense and electronics sectors, which increased by 2.88% and 2.12% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.24% [1] - The agriculture, forestry, animal husbandry, and fishery sectors, along with coal, were the worst performers, declining by 0.85% and 0.70% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets reached 10.37 billion yuan, with 17 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 8.68 billion yuan, coinciding with its 2.12% increase [1] - The power equipment sector also performed well, with a 1.03% increase and a net inflow of 3.76 billion yuan [1] - Conversely, 14 sectors experienced net outflows, with the non-ferrous metals sector leading with a net outflow of 1.635 billion yuan, followed by the basic chemicals sector with 1.212 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector increased by 0.24%, but faced a net outflow of 1.141 billion yuan [2] - Out of 479 stocks in this sector, 320 rose while 134 fell, with one stock hitting the daily limit down [2] - The top three stocks with significant net inflows included C Jianxin with 690 million yuan, followed by Hanyu Pharmaceutical and Innovation Medical with 134 million yuan and 68.69 million yuan respectively [2] - The sector's outflow leaders included Hainan Haiyao with a net outflow of 280 million yuan, followed by Heng Rui Pharmaceutical and Luyan Pharmaceutical with 180 million yuan and 136.53 million yuan respectively [4]
科创板百元股达81只,寒武纪-U股价最高
Zheng Quan Shi Bao Wang· 2025-12-24 09:48
以最新收盘价计算,科创板平均股价为42.60元,其中股价超100元的有81只,股价最高的是寒武纪-U。 证券时报·数据宝统计显示,科创板股今日上涨的有507只,下跌的有90只,以收盘价为基准测算,科创 板平均股价为42.60元,其中,收盘价超过100元的有81只,股价在50元至100元之间的有135只,股价在 30元至50元的有143只。 科创板股中,收盘价最高的是寒武纪-U,今日报收1326.20元,下跌0.74%,其次是源杰科技、摩尔线 程-U等,最新收盘价分别为645.55元、634.01元。 融资融券方面,百元股最新(12月23日)融资余额合计1054.95亿元,融资余额居前的有寒武纪-U、中 芯国际、海光信息等,最新融资余额分别为155.37亿元、130.23亿元、73.90亿元。最新融券余额合计为 4.61亿元,融券余额居前的有海光信息、寒武纪-U、中芯国际等,最新融券余额分别为0.35亿元、0.31 亿元、0.26亿元。(数据宝) 科创板百元股一览 | 代码 | 简称 | 最新收盘价(元) | 今日涨跌(%) | 换手率(%) | 行业 | | --- | --- | --- | --- | - ...
融资买得欢,为何你没赚到?
Sou Hu Cai Jing· 2025-12-24 09:08
最近股市里不少人盯着融资数据看——毕竟真金白银往里砸的方向,总该有机会吧?可身边朋友却念叨:"明明电子、电力设备这些行业融资买得凶,我手 里的股怎么就是不涨?"其实这个问题,早藏在"指数涨了钱没赚"的老麻烦里了。12月23日(周二)Wind统计显示,申万31个一级行业里18个获融资净买 入,电子行业净买入27.65亿元排第一,寒武纪-U、英维克这些个股净买入超2亿。可看着这些数字,有人高兴有人懵:融资砸进去的钱,怎么没落到自己账 户里?别急,文章最后我会说清这个新闻背后的关键,。 很多人觉得牛市是"躺赢局",可股市本来就有博弈属性——你赚的钱是别人亏的,哪有只赚不赔的道理?反而牛市里交投更活跃,大资金更容易用"假突 破""假回调"骗你下车。就像我邻居买的医药生物股,跟着行业融资净买入进去,结果买在"假企稳"的高点,熬了两周才解套——不是他选的行业不对,是 他没看懂走势背后的"冷处理"。 二、走势里的假动作,比你想的多 一、指数涨了钱没赚,真不是分化的锅 自从10月28日上证指数越过4000点,"赚了指数不赚钱"的吐槽就没断过。有人把这归为市场分化,可我翻了组数据——4月7日上证指数止跌企稳到10月30日 破4 ...
科创板系列指数午前反弹,关注科创板50ETF(588080)等产品长期投资价值
Mei Ri Jing Ji Xin Wen· 2025-12-24 07:52
Group 1 - The article discusses various ETFs tracking the Sci-Tech Innovation Board indices, highlighting their focus on high-growth sectors such as semiconductors, medical devices, and software development [2][3] - The Sci-Tech 50 ETF tracks the top 50 stocks by market capitalization and liquidity on the Sci-Tech Innovation Board, with over 65% of its composition in semiconductors and nearly 80% in related sectors [2] - The rolling price-to-earnings (P/E) ratio for the Sci-Tech 50 ETF is reported at 160.0 times, indicating a high valuation level since its inception [2] Group 2 - The Sci-Tech 100 ETF focuses on 100 medium-sized stocks with good liquidity, primarily in the electronics, biomedicine, and electrical equipment sectors, which together account for over 80% of the index [2] - The rolling P/E ratio for the Sci-Tech 100 ETF is noted at 187.8 times, reflecting its valuation dynamics [2] - The Sci-Tech Comprehensive Index ETF covers all market securities on the Sci-Tech Innovation Board, focusing on core industries like artificial intelligence and new energy, with a rolling P/E ratio of 206.9 times [2] Group 3 - The Sci-Tech Growth 50 ETF tracks 50 stocks with high growth rates in revenue and net profit, with nearly 75% of its composition in the electronics and biomedicine sectors [3] - The rolling P/E ratio for the Sci-Tech Growth 50 ETF is reported at 192.0 times, indicating its growth-oriented investment strategy [3] - The article mentions that the management fee for these low-fee products is 0.15% per year, and the custody fee is 0.05% per year [3]
估值重塑与价值重估:聚焦创业板2026两大投资主线
Sou Hu Cai Jing· 2025-12-24 03:44
Core Viewpoint - The ChiNext Index is expected to lead the A-share market in 2026, driven by strong performance and the dual themes of technological independence and anti-involution, indicating a new phase of valuation reshaping and value reassessment [1][4]. Group 1: Technological Independence - The ChiNext serves as the main battleground for new productive forces, benefiting from policy dividends and industry trends, particularly in the fields of electric equipment, electronics, and biomedicine [4]. - As of December 19, 2025, over 70% of the market capitalization in ChiNext is concentrated in the core sectors of new information technology, new energy vehicles, and biomedicine [4]. - Profit margins in electric equipment and electronics have stabilized, with some tech sub-sectors experiencing profit growth rates exceeding 40%, reinforcing the investment value of the technology theme [4]. Group 2: Anti-Involution - The anti-involution policy aims to correct vicious competition in industries facing overcapacity and price wars, which could catalyze profit improvements in key ChiNext sectors like new energy and manufacturing [7]. - The policy is expected to optimize industry competition by regulating market order and eliminating outdated capacity, potentially improving supply-demand dynamics and stabilizing product prices and gross margins [7]. - Companies are likely to focus more on genuine technological innovation and efficiency improvements rather than mere scale expansion, enhancing free cash flow and shareholder returns [7]. Group 3: Investment Opportunities in ChiNext - The ChiNext Index's valuation has fallen to a low level, with a TTM price-to-earnings ratio of 39 times as of December 17, 2025, which is in the 37th percentile over the past decade [8]. - The expected net profit growth rates for the ChiNext Index are 38%, 30%, and 23% for the years 2025, 2026, and 2027, respectively, indicating strong profit growth certainty [8]. - Investors are encouraged to consider ChiNext index ETF products, such as E Fund ChiNext ETF, which ranks high in scale and liquidity among similar index products [9].